Home › Funds › IRIDIAN ASSET MANAGEMENT LLC/CT › NVCT
IRIDIAN ASSET MANAGEMENT LLC/CT position in NVCT
NUVECTIS PHARMA INC · Health Care
IRIDIAN ASSET MANAGEMENT LLC/CT reported holding 793,207 shares of NVCT (NUVECTIS PHARMA INC) in its Q3 2026 13F filing — a position valued at US$16.8M, representing 6.09% of its reported portfolio and ranking #6 among its reported holdings. IRIDIAN ASSET MANAGEMENT LLC/CT has disclosed NVCT holdings in 8 of the last 9 reported quarters, going back to Q3 2024.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How IRIDIAN ASSET MANAGEMENT LLC/CT's NVCT position evolved
IRIDIAN ASSET MANAGEMENT LLC/CT first disclosed a stake in NVCT in Q3 2024 at 55,380 shares (US$348K). The position peaked in Q3 2026 at 793,207 shares, worth US$16.8M. Across 8 filings, IRIDIAN ASSET MANAGEMENT LLC/CT increased the stake 6 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 793,207 shares valued at US$16.8M — an increase of 16,129 shares quarter over quarter.. Notable position changes include a 47% increase in Q2 2025 (shares fell 19% over the following quarter), a 45% increase in Q4 2025 (shares rose 2% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2024 | 55.38K | $348.34K | New |
| Q1 2025 | 253.97K | $2.48M | New |
| Q2 2025 | 372.72K | $2.78M | Add |
| Q3 2025 | 405.62K | $2.44M | Add |
| Q4 2025 | 586.32K | $4.43M | Add |
| Q1 2026 | 651.76K | $5.04M | Add |
| Q2 2026 | 777.08K | $14.29M | Add |
| Q3 2026 | 793.21K | $16.75M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About NVCT and 13F data
NVCT (NUVECTIS PHARMA INC) is a Health Care company. 64 other funds we track also report a position in NVCT — the largest reported positions include TANG CAPITAL MANAGEMENT LLC (US$28.5M), Soleus Capital Management, L.P. (US$18.4M), BALDWIN WEALTH PARTNERS LLC/MA (US$8.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding NVCT
- TANG CAPITAL MANAGEMENT LLC 1.55M sh · $28.50M · Q2 2026
- Soleus Capital Management, L.P. 1.00M sh · $18.39M · Q2 2026
- BALDWIN WEALTH PARTNERS LLC/MA 382.01K sh · $8.07M · Q3 2026
- SPHERA FUNDS MANAGEMENT LTD. 382.94K sh · $7.04M · Q2 2026
- Occam Crest Management LP 4.80K sh · $5.16M · Q2 2026
- Avidity Partners Management LP 200.00K sh · $3.68M · Q2 2026
- Squadron Capital Management LLC 38.70K sh · $711.69K · Q2 2026
More on IRIDIAN ASSET MANAGEMENT LLC/CT
FAQ
How long has IRIDIAN ASSET MANAGEMENT LLC/CT held NVCT?
IRIDIAN ASSET MANAGEMENT LLC/CT has disclosed NVCT holdings in 8 of the last 9 reported quarters, going back to Q3 2024.
What is IRIDIAN ASSET MANAGEMENT LLC/CT's current position in NVCT?
As of Q3 2026, IRIDIAN ASSET MANAGEMENT LLC/CT holds 793.21K shares of NVCT (NUVECTIS PHARMA INC), valued at $16.75M, representing 6.09% of its reported portfolio and ranking #6.
Has IRIDIAN ASSET MANAGEMENT LLC/CT been buying or selling NVCT?
In the latest 13F filing (Q3 2026), IRIDIAN ASSET MANAGEMENT LLC/CT increased its position in NVCT. The position peaked in Q3 2026 at 793.21K shares.
Which other funds hold NVCT?
Other major institutional holders of NVCT include TANG CAPITAL MANAGEMENT LLC, Soleus Capital Management, L.P., BALDWIN WEALTH PARTNERS LLC/MA, among 64 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.